Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2017 - 2024)

KalVista Pharmaceuticals' Other Accumulated Expenses history spans 8 years, with the latest figure at $693000.0 for Q4 2024.

  • For Q4 2024, Other Accumulated Expenses changed N/A year-over-year to $693000.0; the TTM value through Dec 2024 reached $693000.0, changed N/A, while the annual FY2024 figure was $253000.0, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2024 was $693000.0 at KalVista Pharmaceuticals, up from $279000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q3 2024 and bottomed at $47000.0 in Q3 2020.
  • The 4-year median for Other Accumulated Expenses is $200500.0 (2023), against an average of $315916.7.
  • The largest annual shift saw Other Accumulated Expenses tumbled 81.99% in 2020 before it surged 787.84% in 2024.
  • A 4-year view of Other Accumulated Expenses shows it stood at $78000.0 in 2020, then skyrocketed by 58.97% to $124000.0 in 2021, then surged by 153.23% to $314000.0 in 2023, then skyrocketed by 120.7% to $693000.0 in 2024.
  • Per Business Quant, the three most recent readings for KALV's Other Accumulated Expenses are $693000.0 (Q4 2024), $279000.0 (Q4 2024), and $1.3 million (Q3 2024).